School of Medicine Homepage
Emory University Shield
  • About
    • Our Vision
    • Academic Departments
    • Our Leadership
    • Health Care Partnerships
    • Diversity, Equity, & Inclusion
    • Location
    • Supporting Our People
    • Our Faculty
    • History
    • News
    • Events
    • Contact Us
  • Education
    • Degree and Certificate Programs
    • Academic Departments
    • Residents & Fellows
    • Postdoctoral Training
    • Continuing Medical Education
    • Admissions
    • Cost and Financial Aid
    • Student Resources
  • Research
    • Research Innovation
    • Conducting Research
    • Core Facilities
    • Research Centers
    • Research Training
    • Academic Departments
    • Find a Researcher
    • Research News
  • Clinical Experience
    • Where We Work
    • Caring for a Diverse Population
    • Faculty Clinical Experience
    • Advanced Patient Care
    • Academic Departments
    • Community Learning
  • Giving
  • Directory

Directory section navigation

  • Faculty Profiles

Emory University School of Medicine

  • About
    • Sub link
      Our Vision
    • Sub link
      Academic Departments
    • Sub link
      Our Leadership
    • Sub link
      Health Care Partnerships
    • Sub link
      Diversity, Equity, & Inclusion
    • Sub link
      Location
    • Sub link
      Supporting Our People
    • Sub link
      Our Faculty
    • Sub link
      History
    • Sub link
      News
    • Sub link
      Events
    • Sub link
      Contact Us
  • Education
    • Sub link
      Degree and Certificate Programs
    • Sub link
      Academic Departments
    • Sub link
      Residents & Fellows
    • Sub link
      Postdoctoral Training
    • Sub link
      Continuing Medical Education
    • Sub link
      Admissions
    • Sub link
      Cost and Financial Aid
    • Sub link
      Student Resources
  • Research
    • Sub link
      Research Innovation
    • Sub link
      Conducting Research
    • Sub link
      Core Facilities
    • Sub link
      Research Centers
    • Sub link
      Research Training
    • Sub link
      Academic Departments
    • Sub link
      Find a Researcher
    • Sub link
      Research News
  • Clinical Experience
    • Sub link
      Where We Work
    • Sub link
      Caring for a Diverse Population
    • Sub link
      Faculty Clinical Experience
    • Sub link
      Advanced Patient Care
    • Sub link
      Academic Departments
    • Sub link
      Community Learning
  • Giving
  • Directory
  • Home School of Medicine Home
  • Directory

Profile

Yona Levites

  • Department of Pharmacology & Chemical Biology
    Associate Professor
  • yona.levites@emory.edu
  • Lab Website
Head shot of Yona Levites

Overview

Dr. Levites is an Associate Professor at the CND and the Department of Pharmacology and Chemical Biology. She received her PhD in the laboratory of Professor Moussa Youdim at the Technion Israel Institute of Technology, working on the benefits of Green Tea polyphenols in models of Parkinsons Disease. She continued her training as a postdoctoral fellow in the lab of Professor Todd Golde where she developed recombinant antibody fragments against amyloid beta and their delivery to the CNS via Adeno Associated virus. She continued this path at the CTRND at the University of Florida and her primary research there was focused on designing, engineering, and testing recombinant therapies for neurodegenerative disorders. These diseases are characterized by accumulation of misfolded proteins in the brain, initiating a cascade of neurotoxic and inflammatory events leading eventually to brain organ failure. In the recent years immunotherapeutic approach, specifically targeting misfolded proteins accumulation in the CNS has been very promising, although is facing many challenges in clinic. Dr. Levites group cloned variable regions from many newly developed antibodies against these proteins, modified them to increase their stability and efficacy and further test these novel therapeutics in vitro, cell culture, as well as in various mouse models.

The goal of her research is to get preclinical immunotherapy research to the stage where these agents can be evaluated in clinic. Additionally, Dr. Levites is investigating, as a part of a collaborative RF1 project with Drs. Golde, Seyfried and Dr. Prokop (UF), a role of Amyloid Associated Proteins in the pathology of Alzheimers disease. She also plays a key role in developing AAV toolkit, looking for optimal ways to deliver AAV to the CNS and achieve highest levels of gene expression in areas of interest.

Research

Publications

  • Antagonizing Il10 and Il4 signaling via intracerebral decoy receptor expression attenuates A accumulation.
    Acta Neuropathol Commun Volume: 13 Page(s): 51
    03/07/2025 Authors: Koller EJ; McFarland KN; Angelle C; Howard J; Ryu D; Dillon KD; Erquizi A; Beheray M; De La Cruz EG; Cruz PE
  • Integrative proteomics identifies a conserved A amyloid responsome, novel plaque proteins, and pathology modifiers in Alzheimer's disease.
    Cell Rep Med Volume: 5 Page(s): 101669
    08/20/2024 Authors: Levites Y; Dammer EB; Ran Y; Tsering W; Duong D; Abreha M; Gadhavi J; Lolo K; Trejo-Lopez J; Phillips J
  • Proteomic changes in the human cerebrovasculature in Alzheimer's disease and related tauopathies linked to peripheral biomarkers in plasma and cerebrospinal fluid.
    Alzheimers Dement Volume: 20 Page(s): 4043 - 4065
    06/01/2024 Authors: Wojtas AM; Dammer EB; Guo Q; Ping L; Shantaraman A; Duong DM; Yin L; Fox EJ; Seifar F; Lee EB
  • A C1qTNF3 collagen domain fusion chaperones diverse secreted proteins and anti-A scFvs: Applications for gene therapies.
    Mol Ther Methods Clin Dev Volume: 31 Page(s): 101146
    12/14/2023 Authors: Moore BD; Ran Y; Goodwin MS; Komatineni K; McFarland KN; Dillon K; Charles C; Ryu D; Liu X; Prokop S
  • A Amyloid Scaffolds the Accumulation of Matrisome and Additional Proteins in Alzheimer's Disease.
    bioRxiv
    12/07/2023 Authors: Levites Y; Dammer EB; Ran Y; Tsering W; Duong D; Abreha M; Gadhavi J; Lolo K; Trejo-Lopez J; Phillips JL
  • AAV-mediated delivery of an anti-BACE1 VHH alleviates pathology in an Alzheimer's disease model.
    EMBO Mol Med Volume: 14 Page(s): e09824
    04/07/2022 Authors: Marino M; Zhou L; Rincon MY; Callaerts-Vegh Z; Verhaert J; Wahis J; Creemers E; Yshii L; Wierda K; Saito T
  • Intracerebral but Not Peripheral Infection of Live Porphyromonas gingivalis Exacerbates Alzheimer's Disease Like Amyloid Pathology in APP-TgCRND8 Mice.
    Int J Mol Sci Volume: 23
    03/19/2022 Authors: Aravindraja C; Sakthivel R; Liu X; Goodwin M; Veena P; Godovikova V; Fenno JC; Levites Y; Golde TE; Kesavalu L
  • Soluble brain homogenates from diverse human and mouse sources preferentially seed diffuse A plaque pathology when injected into newborn mouse hosts.
    Free Neuropathol Volume: 3 Page(s): 9
    01/11/2022 Authors: Moore BD; Levites Y; Xu G; Hampton H; Adamo MF; Croft CL; Futch HS; Moran C; Fromholt S; Janus C
  • Complexes of Soluble a-Synuclein and Amyloid-beta with Their Cognate Antibodies Activate the NLRP3 Inflammasome in hiPSC-Derived Microglia
    Volume: 90 Page(s): S169 - S169
    10/01/2021 Authors: Trudler D; Nazor KL; Eisele YS; Grabauskas T; Dolatabadi N; Parker J; Sultan A; Zhong Z; Goodwin MS; Levites Y
  • Integrative functional genomic analysis of intron retention in human and mouse brain with Alzheimer's disease.
    Alzheimers Dement Volume: 17 Page(s): 984 - 1004
    06/30/2021 Authors: Li H-D; Funk CC; McFarland K; Dammer EB; Allen M; Carrasquillo MM; Levites Y; Chakrabarty P; Burgess JD; Wang X
  • Modulating innate immune activation states impacts the efficacy of specific A immunotherapy.
    Mol Neurodegener Volume: 16 Page(s): 32
    05/06/2021 Authors: Levites Y; Funk C; Wang X; Chakrabarty P; McFarland KN; Bramblett B; O'Neal V; Liu X; Ladd T; Robinson M
  • Soluble -synuclein-antibody complexes activate the NLRP3 inflammasome in hiPSC-derived microglia.
    Proc Natl Acad Sci U S A Volume: 118
    04/13/2021 Authors: Trudler D; Nazor KL; Eisele YS; Grabauskas T; Dolatabadi N; Parker J; Sultan A; Zhong Z; Goodwin MS; Levites Y
  • Il-10 signaling reduces survival in mouse models of synucleinopathy.
    NPJ Parkinsons Dis Volume: 7 Page(s): 30
    03/19/2021 Authors: Cockey SG; McFarland KN; Koller EJ; Brooks MMT; Gonzalez De La Cruz E; Cruz PE; Ceballos-Diaz C; Rosario AM; Levites YR; Borchelt DR
  • Anti-tau scFvs Targeted to the Cytoplasm or Secretory Pathway Variably Modify Pathology and Neurodegenerative Phenotypes.
    Mol Ther Volume: 29 Page(s): 859 - 872
    02/03/2021 Authors: Goodwin MS; Sinyavskaya O; Burg F; O'Neal V; Ceballos-Diaz C; Cruz PE; Lewis J; Giasson BI; Davies P; Golde TE
  • Biophysical characteristics of lipid-induced A oligomers correlate to distinctive phenotypes in transgenic mice.
    FASEB J Volume: 35 Page(s): e21318
    02/01/2021 Authors: Saha J; Dean DN; Dhakal S; Stockmal KA; Morgan SE; Dillon KD; Adamo MF; Levites Y; Rangachari V
  • A40 displays amyloidogenic properties in the non-transgenic mouse brain but does not exacerbate A42 toxicity in Drosophila.
    Alzheimers Res Ther Volume: 12 Page(s): 132
    10/17/2020 Authors: De Mena L; Smith MA; Martin J; Dunton KL; Ceballos-Diaz C; Jansen-West KR; Cruz PE; Dillon KD; Rincon-Limas DE; Golde TE
  • Meta-Analysis of the Alzheimer's Disease Human Brain Transcriptome and Functional Dissection in Mouse Models.
    Cell Rep Volume: 32 Page(s): 107908
    07/14/2020 Authors: Wan Y-W; Al-Ouran R; Mangleburg CG; Perumal TM; Lee TV; Allison K; Swarup V; Funk CC; Gaiteri C; Allen M
  • Fyn depletion ameliorates tauP301L-induced neuropathology.
    Acta Neuropathol Commun Volume: 8 Page(s): 108
    07/14/2020 Authors: Liu G; Fiock KL; Levites Y; Golde TE; Hefti MM; Lee G
  • Diversity in A deposit morphology and secondary proteome insolubility across models of Alzheimer-typeamyloidosis.
    Acta Neuropathol Commun Volume: 8 Page(s): 43
    04/06/2020 Authors: Xu G; Fromholt SE; Chakrabarty P; Zhu F; Liu X; Pace MC; Koh J; Golde TE; Levites Y; Lewis J
  • Utilizing minimally purified secreted rAAV for rapid and cost-effective manipulation of gene expression in the CNS.
    Mol Neurodegener Volume: 15 Page(s): 15
    03/02/2020 Authors: Goodwin MS; Croft CL; Futch HS; Ryu D; Ceballos-Diaz C; Liu X; Paterno G; Mejia C; Deng D; Menezes K
  • Neurite orientation dispersion and density imaging reveals white matter and hippocampal microstructure changes produced by Interleukin-6 in the TgCRND8 mouse model of amyloidosis.
    Neuroimage Volume: 202 Page(s): 116138
    11/15/2019 Authors: Colon-Perez LM; Ibanez KR; Suarez M; Torroella K; Acuna K; Ofori E; Levites Y; Vaillancourt DE; Golde TE; Chakrabarty P
  • An anti-CRF antibody suppresses the HPA axis and reverses stress-induced phenotypes.
    J Exp Med Volume: 216 Page(s): 2479 - 2491
    11/04/2019 Authors: Futch HS; McFarland KN; Moore BD; Kuhn MZ; Giasson BI; Ladd TB; Scott KA; Shapiro MR; Nosacka RL; Goodwin MS
  • Intra- and extracellular -amyloid overexpression via adeno-associated virus-mediated gene transfer impairs memory and synaptic plasticity in the hippocampus.
    Sci Rep Volume: 9 Page(s): 15936
    11/04/2019 Authors: Forner S; Martini AC; Prieto GA; Dang CT; Rodriguez-Ortiz CJ; Reyes-Ruiz JM; Trujillo-Estrada L; da Cunha C; Andrews EJ; Phan J
  • AAV-mediated delivery of a novel anti-BACE1 VHH reduces Abeta in an Alzheimer's disease mouse model
    Volume: 30 Page(s): A95 - A95
    11/01/2019 Authors: Rincon MY; Zhou L; Marneffe C; Voytyuk I; Wouters Y; Dewilde M; Duque SI; Vincke C; Levites Y; Golde TE
  • Comparative analyses of the in vivo induction and transmission of -synuclein pathology in transgenic mice by MSA brain lysate and recombinant -synuclein fibrils.
    Acta Neuropathol Commun Volume: 7 Page(s): 80
    05/20/2019 Authors: Dhillon J-KS; Trejo-Lopez JA; Riffe C; Levites Y; Sacino AN; Borchelt DR; Yachnis AY; Giasson BI
  • Magnetic resonance-based axonal microstructure measures are differentially modulated by interleukin-6 in amyloid expressing TgCRND8 mice
    Volume: 33
    04/01/2019 Authors: Febo M; Colon-Perez LM; Ibanez KR; Suarez MR; Acuna KR; Levites Y; Ofori E; Vaillancourt DE; Golde TE; Chakrabarty P
  • rAAV-based brain slice culture models of Alzheimer's and Parkinson's disease inclusion pathologies.
    J Exp Med Volume: 216 Page(s): 539 - 555
    03/04/2019 Authors: Croft CL; Cruz PE; Ryu DH; Ceballos-Diaz C; Strang KH; Woody BM; Lin W-L; Deture M; Rodrguez-Lebrn E; Dickson DW
  • Short A peptides attenuate A42 toxicity in vivo.
    J Exp Med Volume: 215 Page(s): 283 - 301
    01/02/2018 Authors: Moore BD; Martin J; de Mena L; Sanchez J; Cruz PE; Ceballos-Diaz C; Ladd TB; Ran Y; Levites Y; Kukar TL
  • Designing antibodies against LRRK2-targeted tau epitopes.
    PLoS One Volume: 13 Page(s): e0204367
    01/01/2018 Authors: Hamm M; Ladd TB; Levites Y; Golde TE; Giasson BI; Lewis J
  • Novel monoclonal antibodies targeting the microtubule-binding domain of human tau.
    PLoS One Volume: 13 Page(s): e0195211
    01/01/2018 Authors: Croft CL; Moore BD; Ran Y; Chakrabarty P; Levites Y; Golde TE; Giasson BI
  • Generation and characterization of new monoclonal antibodies targeting the PHF1 and AT8 epitopes on human tau.
    Acta Neuropathol Commun Volume: 5 Page(s): 58
    07/31/2017 Authors: Strang KH; Goodwin MS; Riffe C; Moore BD; Chakrabarty P; Levites Y; Golde TE; Giasson BI
  • Strain-specific Fibril Propagation by an A Dodecamer.
    Sci Rep Volume: 7 Page(s): 40787
    01/18/2017 Authors: Dean DN; Das PK; Rana P; Burg F; Levites Y; Morgan SE; Ghosh P; Rangachari V
  • Holdase activity of secreted Hsp70 masks amyloid-42 neurotoxicity in Drosophila.
    Proc Natl Acad Sci U S A Volume: 113 Page(s): E5212 - E5221
    08/30/2016 Authors: Fernandez-Funez P; Sanchez-Garcia J; de Mena L; Zhang Y; Levites Y; Khare S; Golde TE; Rincon-Limas DE
  • Deficits in hippocampal-dependent transfer generalization learning accompany synaptic dysfunction in a mouse model of amyloidosis.
    Hippocampus Volume: 26 Page(s): 455 - 471
    04/01/2016 Authors: Montgomery KS; Edwards G; Levites Y; Kumar A; Myers CE; Gluck MA; Setlow B; Bizon JL
  • Anti-A single-chain variable fragment antibodies exert synergistic neuroprotective activities in Drosophila models of Alzheimer's disease.
    Hum Mol Genet Volume: 24 Page(s): 6093 - 6105
    11/01/2015 Authors: Fernandez-Funez P; Zhang Y; Sanchez-Garcia J; de Mena L; Khare S; Golde TE; Levites Y; Rincon-Limas DE
  • IFN- promotes phosphorylation without affecting mature tangles.
    FASEB J Volume: 29 Page(s): 4384 - 4398
    10/01/2015 Authors: Li A; Ceballos-Diaz C; DiNunno N; Levites Y; Cruz PE; Lewis J; Golde TE; Chakrabarty P
  • A human monoclonal IgG that binds a assemblies and diverse amyloids exhibits anti-amyloid activities in vitro and in vivo.
    J Neurosci Volume: 35 Page(s): 6265 - 6276
    04/22/2015 Authors: Levites Y; O'Nuallain B; Puligedda RD; Ondrejcak T; Adekar SP; Chen C; Cruz PE; Rosario AM; Macy S; Mably AJ
  • Widespread and efficient transduction of spinal cord and brain following neonatal AAV injection and potential disease modifying effect in ALS mice.
    Mol Ther Volume: 23 Page(s): 53 - 62
    01/01/2015 Authors: Ayers JI; Fromholt S; Sinyavskaya O; Siemienski Z; Rosario AM; Li A; Crosby KW; Cruz PE; DiNunno NM; Janus C
  • Intracerebroventricular viral injection of the neonatal mouse brain for persistent and widespread neuronal transduction.
    J Vis Exp Page(s): 51863
    09/15/2014 Authors: Kim J-Y; Grunke SD; Levites Y; Golde TE; Jankowsky JL
  • Induction of CNS -synuclein pathology by fibrillar and non-amyloidogenic recombinant -synuclein.
    Acta Neuropathol Commun Volume: 1 Page(s): 38
    07/17/2013 Authors: Sacino AN; Brooks M; McGarvey NH; McKinney AB; Thomas MA; Levites Y; Ran Y; Golde TE; Giasson BI
  • Robust cytoplasmic accumulation of phosphorylated TDP-43 in transgenic models of tauopathy.
    Acta Neuropathol Volume: 126 Page(s): 39 - 50
    07/01/2013 Authors: Clippinger AK; D'Alton S; Lin W-L; Gendron TF; Howard J; Borchelt DR; Cannon A; Carlomagno Y; Chakrabarty P; Cook C
  • Viral transduction of the neonatal brain delivers controllable genetic mosaicism for visualising and manipulating neuronal circuits in vivo.
    Eur J Neurosci Volume: 37 Page(s): 1203 - 1220
    04/01/2013 Authors: Kim J-Y; Ash RT; Ceballos-Diaz C; Levites Y; Golde TE; Smirnakis SM; Jankowsky JL
  • Capsid serotype and timing of injection determines AAV transduction in the neonatal mice brain.
    PLoS One Volume: 8 Page(s): e67680
    01/01/2013 Authors: Chakrabarty P; Rosario A; Cruz P; Siemienski Z; Ceballos-Diaz C; Crosby K; Jansen K; Borchelt DR; Kim J-Y; Jankowsky JL
  • Overlapping profiles of A peptides in the Alzheimer's disease and pathological aging brains.
    Alzheimers Res Ther Volume: 4 Page(s): 18
    05/23/2012 Authors: Moore BD; Chakrabarty P; Levites Y; Kukar TL; Baine A-M; Moroni T; Ladd TB; Das P; Dickson DW; Golde TE
  • A alters the connectivity of olfactory neurons in the absence of amyloid plaques in vivo.
    Nat Commun Volume: 3 Page(s): 1009
    01/01/2012 Authors: Cao L; Schrank BR; Rodriguez S; Benz EG; Moulia TW; Rickenbacher GT; Gomez AC; Levites Y; Edwards SR; Golde TE
  • Bispecific tandem single chain antibody simultaneously inhibits -secretase and promotes -secretase processing of APP.
    J Alzheimers Dis Volume: 28 Page(s): 961 - 969
    01/01/2012 Authors: Boddapati S; Levites Y; Suryadi V; Kasturirangan S; Sierks MR
  • Inhibiting -secretase activity in Alzheimer's disease cell models with single-chain antibodies specifically targeting APP.
    J Mol Biol Volume: 405 Page(s): 436 - 447
    01/14/2011 Authors: Boddapati S; Levites Y; Sierks MR
  • Massive gliosis induced by interleukin-6 suppresses Abeta deposition in vivo: evidence against inflammation as a driving force for amyloid deposition.
    FASEB J Volume: 24 Page(s): 548 - 559
    02/01/2010 Authors: Chakrabarty P; Jansen-West K; Beccard A; Ceballos-Diaz C; Levites Y; Verbeeck C; Zubair AC; Dickson D; Golde TE; Das P
  • Generating differentially targeted amyloid-beta specific intrabodies as a passive vaccination strategy for Alzheimer's disease.
    Mol Ther Volume: 17 Page(s): 2031 - 2040
    12/01/2009 Authors: Sudol KL; Mastrangelo MA; Narrow WC; Frazer ME; Levites YR; Golde TE; Federoff HJ; Bowers WJ
  • Quantitative and mechanistic studies of Abeta immunotherapy.
    CNS Neurol Disord Drug Targets Volume: 8 Page(s): 31 - 49
    03/01/2009 Authors: Golde TE; Das P; Levites Y
  • BRI2 (ITM2b) inhibits Abeta deposition in vivo.
    J Neurosci Volume: 28 Page(s): 6030 - 6036
    06/04/2008 Authors: Kim J; Miller VM; Levites Y; West KJ; Zwizinski CW; Moore BD; Troendle FJ; Bann M; Verbeeck C; Price RW
  • Rab5 mediates an amyloid precursor protein signaling pathway that leads to apoptosis.
    J Neurosci Volume: 27 Page(s): 7141 - 7153
    07/04/2007 Authors: Laifenfeld D; Patzek LJ; McPhie DL; Chen Y; Levites Y; Cataldo AM; Neve RL
  • Insights into the mechanisms of action of anti-Abeta antibodies in Alzheimer's disease mouse models.
    FASEB J Volume: 20 Page(s): 2576 - 2578
    12/01/2006 Authors: Levites Y; Smithson LA; Price RW; Dakin RS; Yuan B; Sierks MR; Kim J; McGowan E; Reed DK; Rosenberry TL
  • Intracranial adeno-associated virus-mediated delivery of anti-pan amyloid beta, amyloid beta40, and amyloid beta42 single-chain variable fragments attenuates plaque pathology in amyloid precursor protein mice.
    J Neurosci Volume: 26 Page(s): 11923 - 11928
    11/15/2006 Authors: Levites Y; Jansen K; Smithson LA; Dakin R; Holloway VM; Das P; Golde TE
  • Interleukin-1 receptor 1 knockout has no effect on amyloid deposition in Tg2576 mice and does not alter efficacy following Abeta immunotherapy.
    J Neuroinflammation Volume: 3 Page(s): 17
    07/26/2006 Authors: Das P; Smithson LA; Price RW; Holloway VM; Levites Y; Chakrabarty P; Golde TE
  • Devising A beta-Specific Passive Immunization Strategies for Alzheimer's Disease Using rAAV Vector-Mediated scFv Antibody Delivery
    Volume: 13 Page(s): S94 - S95
    05/01/2006 Authors: Fowlkes KL; Mastrangelo MA; Narrow WC; Levites Y; Golde TE; Federoff HJ; Bowers WJ
  • Anti-Abeta42- and anti-Abeta40-specific mAbs attenuate amyloid deposition in an Alzheimer disease mouse model.
    J Clin Invest Volume: 116 Page(s): 193 - 201
    01/01/2006 Authors: Levites Y; Das P; Price RW; Rochette MJ; Kostura LA; McGowan EM; Murphy MP; Golde TE
  • Anti-A beta(1-16), A beta(35-40) and A beta(35-42) single-chain variable region fragments as potential therapeutic agents for AD
    Volume: 25 Page(s): S573 - S573
    07/01/2004 Authors: Levites Y; Das P; Golde TE
  • Neuroprotection and neurorescue against Abeta toxicity and PKC-dependent release of nonamyloidogenic soluble precursor protein by green tea polyphenol (-)-epigallocatechin-3-gallate.
    FASEB J Volume: 17 Page(s): 952 - 954
    05/01/2003 Authors: Levites Y; Amit T; Mandel S; Youdim MBH
  • Iron chelators-radical scavengers 3,3-epigallocatechin-3-gallate (EGCG) from tea extract and apomorphine attenuate neuronal cell death in 6-hydroxydopamine and MPTP models of Parkinson's Disease: Possible gene targets employing CDNA microarray
    BIOMETALS Volume: 16 Page(s): 228 - 228
    03/01/2003 Authors: Youdim MBH; Mandel S; Maor G; Levites Y
  • Neuroprotective strategies in Parkinson's disease : an update on progress.
    CNS Drugs Volume: 17 Page(s): 729 - 762
    01/01/2003 Authors: Mandel S; Grnblatt E; Riederer P; Gerlach M; Levites Y; Youdim MBH
  • Involvement of protein kinase C activation and cell survival/ cell cycle genes in green tea polyphenol (-)-epigallocatechin 3-gallate neuroprotective action.
    J Biol Chem Volume: 277 Page(s): 30574 - 30580
    08/23/2002 Authors: Levites Y; Amit T; Youdim MBH; Mandel S
  • C-DNA Microarray to determine molecular events in neurodegeneration and neuroprotection
    Volume: 81 Page(s): 4 - 4
    06/01/2002 Authors: Youdim MBH; Levites Y; Weinreb O; Mandel S
  • A unique neuroprotective mechanism of action of green tea component (-)-epigallocatechin-3-gallate, via specific activation of protein kinase c and modulation of cell survival genes
    Volume: 33 Page(s): S206 - S206
    01/01/2002 Authors: Mandel S; Levites Y; Amit T; Youdim MBH
  • Neuroprotection/neurorescue actions and regulation of APP processing by the major green tea polyphenol, EGCG: Involvement of PKC.
    Volume: 33 Page(s): S205 - S206
    01/01/2002 Authors: Levites Y; Amit T; Mandel S; Youdim MBH
  • What can be learnt from cDNA microarray gene expression about oxidative stress in dopaminergic neuron death and Parkinson's disease?
    Volume: 33 Page(s): S115 - S116
    01/01/2002 Authors: Youdim MBH; Levites Y; Grunblatt E; Weinreb O; Mandel S
  • Attenuation of 6-hydroxydopamine (6-OHDA)-induced nuclear factor-kappaB (NF-kappaB) activation and cell death by tea extracts in neuronal cultures.
    Biochem Pharmacol Volume: 63 Page(s): 21 - 29
    01/01/2002 Authors: Levites Y; Youdim MBH; Maor G; Mandel S
  • Early and late molecular events in neurodegeneration and neuroprotection in Parkinson's disease MPTP model as assessed by cDNA microarray; the role of iron.
    Neurotox Res Volume: 4 Page(s): 679 - 689
    01/01/2002 Authors: Youdim MBH; Grnblatt E; Levites Y; Maor G; Mandel S
  • Neuroprotective actions of green tea polyphenol, (-)-epigallocatechin-3-gallate in models of Parkinson's disease: Gene targets
    Volume: 53 Page(s): 463 - 466
    01/01/2002 Authors: Mandel S; Levites Y; Weinreb O; Youdim MBH
  • Green tea polyphenol (-)-epigallocatechin-3-gallate prevents N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced dopaminergic neurodegeneration.
    J Neurochem Volume: 78 Page(s): 1073 - 1082
    09/01/2001 Authors: Levites Y; Weinreb O; Maor G; Youdim MB; Mandel S
Read more publications Fewer publications
Directory
  • Faculty Profiles
Emory University Homepage

Contact & Location

Emory University School of Medicine
100 Woodruff Circle
Atlanta, GA  30322 USA
  • Contact Us
  • Maps & Directions
  • Careers

Information For

  • Alumni
  • Faculty & Staff
  • Patients
  • Residents & Fellows
  • Students
Support the School of Medicine School of Medicine Intranet
facebook facebook twitter twitter linkedin linkedin instagram instagram youtube youtube
© 2025 Emory University
  • Privacy Policy
  • Emergency Information
  • EEO Employer-Disability/Veteran Statements